When Life Science Intelligence (LSI) launched its first LSI Europe conference in London in 2022, it marked an inflection point for Hypervision Surgical (“Hypervision”). At that inaugural event, we met HERAN Partners, who went on to co-lead our £6.5 million seed investment round alongside Redalpine, LifeX Ventures and ZEISS Ventures. Those first conversations laid the foundation for a strong partnership and the continued growth of our company.
This year, LSI Europe returned to London — and Hypervision returned as one of its success stories. With our sights now set on raising our Series A financing round to bring our pioneering Hyperspectral Intelligence® platform to market, we’re building on our momentum and continuing our journey of innovation and growth.
Michael Ebner, CEO of Hypervision, and Raf Roelands, Partner at HERAN Partners, in front of a conference video display featuring highlights from Hypervision’s presentations at multiple LSI events — beginning with LSI Europe 2022, where their initial connection ultimately led to the company’s £6.5M seed investment round.
Spotlight on the LSI Signature Series
Beyond engaging with leading investors, medtech entrepreneurs, and key stakeholders in the field, a standout moment this year was Hypervision’s inclusion in the LSI Signature Series. Our CEO Michael Ebner joined our Chair Martin Frost on stage to share both an update on recent milestones, including
- FDA clearance for general surgery — the first ever for real-time spectral imaging in surgery
- Strategic venture partnership with imec — developing next-gen spectral sensing for surgery
- Securing 2nd place at the Society of Robotic Surgery Shark Tank competition — recognising breakthrough innovation in digital surgery,
and a deeper insight into our journey of pioneering AI-enabled spectral imaging to unlock the next generation of data-driven, intraoperative decision-making.
Martin Frost, Chair of Hypervision, and Michael Ebner, CEO, discussing the journey of Hypervision on-stage as part of LSI’s Signature Series.
The conversation explored Hypervision’s approach to building its team and board for growth, selecting the right people at the right time, and creating a culture of commercially-driven innovation. As a first-time entrepreneur and scientist-turned-CEO, Michael shared reflections on lessons learned and ongoing challenges in translating cutting-edge research into a growing venture-backed business, while Martin complemented this with insights shaped by decades of leadership, boardroom service, and investing experience.
Martin’s perspective was especially valuable given his exceptional track record in medtech and technology leadership. He co-founded and led CMR Surgical, one of the UK’s most successful medtech companies, and also served as CEO of Sagentia, a leading international technology and product development consultancy. His expertise in scaling businesses, building high-performing teams, and raising capital adds a crucial dimension to Hypervision’s board and strategic direction as the company moves toward its Series A and commercialisation phase.
Together on stage, Michael and Martin underscored how Hypervision is solidifying its foundation for scale — and how relationships forged through platforms like LSI continue to drive forward our mission to unlock a new era of surgical intelligence for every procedure.
See more pictures in our LinkedIn post.